Site name unknown Jerusalem

Phase	Trial	Trial Status	Site Status	Drug [desc]	NCT#
2	Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor	Completed	Closed	Nilotinib	NCT00633295